Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.

× No keyword cloud information.

14 in total

1. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

Authors: Asma Bashir; Sofie Mathilde Jacobsen; Otto Mølby Henriksen; Helle Broholm; Thomas Urup; Kirsten Grunnet; Vibeke Andrée Larsen; Søren Møller; Jane Skjøth-Rasmussen; Hans Skovgaard Poulsen; Ian Law
Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300

Review 2. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Authors: Norbert Galldiks; Karl-Josef Langen; Whitney B Pope
Journal: Neuro Oncol Date: 2015-06-30 Impact factor: 12.300

3. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Authors: Norbert Galldiks; Veronika Dunkl; Garry Ceccon; Caroline Tscherpel; Gabriele Stoffels; Ian Law; Otto M Henriksen; Aida Muhic; Hans S Poulsen; Jan Steger; Elena K Bauer; Philipp Lohmann; Matthias Schmidt; Nadim J Shah; Gereon R Fink; Karl-Josef Langen
Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-07 Impact factor: 9.236

4. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

Authors: Garry Ceccon; Lazaros Lazaridis; Gabriele Stoffels; Marion Rapp; Manuel Weber; Tobias Blau; Phillip Lohmann; Sied Kebir; Ken Herrmann; Gereon R Fink; Karl-Josef Langen; Martin Glas; Norbert Galldiks
Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-21 Impact factor: 9.236

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.

1. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

Review 2. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

3. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

4. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

5. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

6. Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure.

Review 7. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.

Review 8. Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients.

Review 9. Usefulness of positron emission tomographic studies for gliomas.

10. Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?